Condition: Inborn Errors of Immunity · Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
The aim of the current study is to evaluate the efficacy of combined regimen of GVHD prophylaxis with thymoglobulin in conditioning regimen and PTCY with ruxolitinib used after HSCT in patients with inborn errors of immunity (IEI)
This description comes directly from the study's public registry record.
Dmitry Balashov, MD, PhD · +74956647091 · bala8@yandex.ru
Alexandra Laberko, MD, PhD · 74952876570 · alexandra.laberko@gmail.com
Always discuss trial participation with your own doctor first.
| HSCT department | Moscow, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06199427